相关实验视频

Updated: Jul 24, 2025

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

结果和处方实践中的性别差异在ST升高MI中患有多血管疾病和不完全再血管化的患者

Sonya Burgess^1,2,3,4, Craig P Juergens^1,2, Wesley Yang¹

¹Cardiology Department, Ingham Institute at Liverpool Hospital Sydney, Australia.

European cardiology

|July 5, 2023

概括

在ST升高心肌梗塞 (STEMI) 中的性别差异仍然存在,女性心脏病死亡率和心脏病发作率更高. 多血管疾病和女性对P2Y12抑制剂的处方不足有助于这些较差的结果.

科学领域:

心脏病学心脏病学
干预心脏病学干预心脏病学
健康结果研究研究结果

背景情况:

在ST升高心肌梗塞 (STEMI) 患者中存在基于性别的结果差异.
多血管疾病 (MVD) 和不完全的再血管化是常见的挑战.
了解导致结果差异的因素对于改善患者护理至关重要.

研究的目的:

量化MVD,不完整的再血管化和处方模式对STEMI患者基于性别的结果差异的影响.
为了确定心脏死亡和心肌梗塞 (CDMI) 率差异是否在长期随访中持续存在.

主要方法:

对2,083名连续STEMI患者进行皮肤冠状动脉干预的观察研究.
对MVD,残留SYNTAX得分 (rSS) 和CDMI率的基于性别差异的分析.
多变量分析以确定CDMI的独立预测因子,包括性别和MVD.

主要成果:

女性 (20.3%) 的CDMI比男性 (20.3%) 的CDMI比男性 (13.2%) 的CDMI更高 (p=0.028),在风险调整后仍然存在 (aHR 1.33).
患有MVD的女性的CDMI比率不成比例地高 (p<0.001).
女性接受指南推的P2Y12抑制剂的频率低于男性 (31%对43%,p=0.012),特别是那些患有MVD (25%对45%,p=0.011).

结论:

在STEMI患者中,基于性别的结果差异长期存在,特别是在患有MVD的女性中.
在女性中,不完整的重血管化和低于最佳的P2Y12抑制剂的处方可能会加剧不良结果.
解决这些差异对于公平的STEMI患者护理至关重要.

关键词:

抗血小板治疗是一种抗血小板疗法.在这里,我们可以看到MI MI MI MI MI.心脏病死亡心脏病死亡不完全的重血管化.多血管冠状动脉疾病冠状动脉疾病女人女人女人女人女人

更多相关视频

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

相关概念视频

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Acute Coronary Syndrome III: Diagnostic Studies

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...

Acute Coronary Syndrome IV: Interprofessional Care

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...